Table 2: CISS score, NPC and PFV data recorded at the end of the 12th week of therapy.

Group I Group II
CISS<16 Improvement ≥10 17 (32.7%) 22 (44%)
Improvement <10 9 (17.3%) 13 (26%)
CISS>16 Improvement ≥10 13 (25%) 9 (18%)
Improvement <10 13 (25%) 6 (12%)
Statistical Significance from Baseline X2=3.19, p<0.05
NPC<6 & Improvement ≥4 24 (46.2%) 38 (76%)
NPC<6 & Improvement <4 16 (30.7%) 5 (10%)
NPC>6 & Improvement ≥4 12 (23.1%) 7 (14%)
Statistical Significance from Baseline X2=3.257, p<0.05
Normal PFV & Improvement >10Δ 22 (42.3%) 32 (64%)
Normal PFV & Improvement ≤10Δ 16 (30.8%) 14 (28%)
Insufficient PFV & Improvement >10Δ 14 (26.9%) 4 (8%)
Statistical Significance X2=5.195, p<0.05

Data are presented as mean ±SD & numbers; percentages are in parenthesis; CISS: Convergence insufficiency Symptom Survey score; NPC: Near convergence point; PFV: positive fusional vergence